| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Prime Medicine, Inc. | SVP, Strategy & Corporate Ops. | Stock Option (right to buy) | 90,500 | 27 Feb 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| PRME | Prime Medicine, Inc. | 27 Feb 2025 | 1 | $0 | 4 | SVP, Strategy & Corporate Ops. | 03 Mar 2025, 20:16 |
| PRME | Prime Medicine, Inc. | 21 Feb 2024 | 1 | $0 | 4 | SVP, Strategy & Corporate Ops. | 23 Feb 2024, 17:02 |
| PRME | Prime Medicine, Inc. | 18 Apr 2023 | 1 | $0 | 4 | SVP, Strategy & Corporate Ops. | 20 Apr 2023, 16:25 |
| PRME | Prime Medicine, Inc. | 31 Mar 2023 | 1 | $0 | 4 | SVP, Strategy & Corporate Ops. | 04 Apr 2023, 20:23 |
| PRME | Prime Medicine, Inc. | 19 Oct 2022 | 0 | $0 | 3 | SVP, Strategy & Corporate Ops. | 19 Oct 2022, 20:06 |